Nanomedicine approaches for corneal diseases.
Nanomedicine approaches for corneal diseases.
复制标题
DOI：
10.3390/jfb6020277
复制
发表时间：
2015-04-30
影响因子：
4.8
通讯作者：
Mohan RR
中科院分区：
文献类型：
--
作者：
Chaurasia SS;Lim RR;Lakshminarayanan R;Mohan RR
角膜疾病是全球第三大致盲原因。局部非甾体抗炎药（NSAID），类固醇，抗生素和组织移植目前用于治疗角膜病理条件。然而，眼表面的屏障性质需要在眼中重复施用高浓度的药物。这通常会导致疗效差和一些副作用。基于纳米颗粒的分子医学试图通过增强药物的渗透性和药理学性质来克服这些限制。在临床前动物研究中，纳米医学方法治疗角膜缺损和恢复视力而无副作用的前景已经得到证实。已经鉴定了许多能够将基因转运到所需角膜细胞中以阻断导致失明的病理途径和过程的聚合物、金属和混合纳米颗粒。本文综述了角膜疾病、纳米载体的性质及其在药物递送和角膜疾病管理中的应用。
Corneal diseases are the third leading cause of blindness globally. Topical nonsteroidal anti-inflammatory drugs (NSAIDs), steroids, antibiotics and tissue transplantation are currently used to treat corneal pathological conditions. However, barrier properties of the ocular surface necessitate high concentration of the drugs applied in the eye repeatedly. This often results in poor efficacy and several side-effects. Nanoparticle-based molecular medicine seeks to overcome these limitations by enhancing the permeability and pharmacological properties of the drugs. The promise of nanomedicine approaches for treating corneal defects and restoring vision without side effects in preclinical animal studies has been demonstrated. Numerous polymeric, metallic and hybrid nanoparticles capable of transporting genes into desired corneal cells to intercept pathologic pathways and processes leading to blindness have been identified. This review provides an overview of corneal diseases, nanovector properties and their applications in drug-delivery and corneal disease management.